Interventional {{label}}

Talampanel Clinical Trial in ALS Patients

Please note: All trial information reflects the latest data available from the sponsor on ClinicalTrials.gov and other public databases. However, these sources may occasionally be outdated or inaccurate. For the most current information, we recommend contacting the trial sponsor or sites directly.

Overview

Intervention or Drug Name

Sponsor

Trial Status

Phase

Randomization

Trial Duration

Route of Administration

Genetic Target

Repurposed Drugs

Approved by FDA

Approved outside USA

Is a supplement

Details

Enrollment Criteria

Time since symptom onset

Vital Capacity (FVC or SVC)

Approved Medications

Registry Listing

{{trial.ExternalId}} (First Published: {{trial.FirstPublishedDate|date}} on {{trial.SourceName}})

Purpose

To determine the efficacy ad long-term safety and tolerability of talampanel treatment in ALS.

What participation looks like

Single dose of 50mg 3 X day.

This drug is thought to be antiglutamatergic and testing in SOD1 mice showed a positive effect on survival. T

However, on May 10, 2010 the company managing the trial announced that its phase II trial did not meet its primary endpoints, although the drug was reported to be safe and well tolerated in patients.

A link to that press release is as follows: http://www.marketwatch.com/story/teva-provides-update-on-talampanel-for-the-treatment-of-amyotrophic-lateral-sclerosis-als-2010-05-17

Eligibility criteria

Ages 18-80. Both Genders. No healthy volunteers.

Locations

{{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}

{{location.Facility !== '' ? location.Facility + ',' : ''}} {{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}

Location Contact: {{location.Contact.Name}} {{location.Contact.Name}} Phone: {{location.Contact.Phone}}

Join the ALS Research Collaborative (ARC) Study Today!

Ready to make a difference in ALS research?

Join the ARC Study! Whether you're living with ALS or an asymptomatic gene carrier, your participation can help inform ALS research and lead to new treatments.

Learn More

Thank You to Our Sponsors